Catalog No.: PC-21026Not For Human Use, Lab Use Only.
AS2676293 (AS 2676293) is an orally active small-molecule receptor activator of nuclear factor-κB ligand (RANKL) inhibitor, inhibits RANKL-induced osteoclastogenesis using RAW264 cells with IC50 of 0.19 uM.
AS2676293 (AS 2676293) is an orally active small-molecule receptor activator of nuclear factor-κB ligand (RANKL) inhibitor, inhibits RANKL-induced osteoclastogenesis using RAW264 cells with IC50 of 0.19 uM.
AS2676293 (0.3-3 mg/kg, oral) inhibited bone loss significantly in RANKL-induced osteopenic mice.
AS2676293 markedly inhibited bone metastasis of human breast cancer cells MDA-MB-231-5a-D-Luc2 as well as tumour-induced osteolysis.
AS2676293 suppressed RANKL-mediated tumour migration in the transwell assay and inhibited bone metastasis of the murine cell line B16F10, which is known not to trigger osteoclast activation.
